Clinical trials: Advanced Urothelial Carcinoma
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Carcinoma, Transitional Cell
Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer
This is a clinical trial to evaluate the efficacy and safety of the drug vinflunine administered after the standard treatment of the combination gemcitabine+cisplatin, when it has reached stabilization or response of the disease…
- Trial name
- MAJA (NCT01529411)
- Testing
- Vinflunine, Undefined (standard care)
- Where
- 20 sites in Spain
- Volunteers
- 86 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Advanced Solid Tumors, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
- Conditions
- Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC
- Trial name
- NCT04272034
- Testing
- INCB099318
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Incyte Corporation
Urothelial Cancer, Bladder Cancer
Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
This study will evaluate the safety and efficacy of the combination of ABI-007, carboplatin and gemcitabine in the treatment of patients with advanced bladder cancer.
- Trial name
- NCT00995488
- Testing
- ABI-007 (Abraxane®)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center
Urothelial Carcinoma
Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma
Platinum-based chemotherapy is now regarded a standard first-line treatment for patients with advanced urothelial carcinoma (UC).
- Trial name
- NCT02535650
- Testing
- tipifarnib
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Samsung Medical Center
Urothelial Carcinoma
Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma
The purpose of this research study is to test the safety of avelumab and AVB-S6-500 and see what effects (good and bad) this combination treatment has on patients with advanced urothelial carcinoma.
- Trial name
- COAXIN (NCT04004442)
- Testing
- Avelumab, AVB-S6-500
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Oklahoma
Locally Advanced or Metastatic Urothelial Carcinoma
A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
The study is being conducted to evaluate the efficacy of SHR-A2102 with adebrelimab versus gemcitabine in combination with cisplatin/carboplatin in previously untreated locally advanced or metastatic urothelial carcinoma.
- Trial name
- NCT07393542
- Testing
- SHR-A2102 and Adebrelimab, Gemcitabine and cisplatin / carboplatin
- Where
- China
- Volunteers
- 453 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Transitional Cell Carcinoma of the Bladder, Biomarkers
Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab
In the RESPONDER study, the role of the immune evasive mechanisms combined with genomic characterization will be explored in urothelial cancer patients treated with second-line treatment with pembrolizumab.
- Trial name
- RESPONDER (NCT03263039)
- Testing
- Pembrolizumab
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Erasmus Medical Center
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
- Trial name
- NCT03739931
- Testing
- mRNA-2752, Durvalumab
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 134 people
- Sponsor
- ModernaTX, Inc.
Urothelial Carcinoma
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra).
- Trial name
- NCT05911295
- Testing
- disitamab vedotin, pembrolizumab, gemcitabine
- Where
- 268 sites in United States, Argentina and 22 more
- Volunteers
- 412 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Urothelial Carcinoma
KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
This is a two-part (dose-escalation, dose-expansion), multicenter, open-label Phase 1 study of KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic urothelial carcinoma (including bladder…
- Trial name
- NCT03915405
- Testing
- KHK2455, Avelumab
- Where
- 9 sites in United States, Spain
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin, Inc.
Urothelial Carcinoma, Solid Tumor
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
This phase II study is designed to explore the efficacy and safety of SI-B003 monotherapy and BL-B01D1+SI-B003 combination therapy in patients with locally advanced or metastatic urothelial carcinoma and other solid tumors.
- Trial name
- NCT05965856
- Testing
- BL-B01D1, SI-B003
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Urothelial Carcinoma
A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547
Phase 1b clinical study to evaluate the PK of oral AZD4547 in Chinese patients and RP2D. Phase 2 study to evaluate the efficacy of AZD4547 in urothelial carcinoma patients with FGFR2/3 gene alterations.
- Trial name
- NCT05086666
- Testing
- AZD4547
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Urothelial Cancer
RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy
This is a pilot study of a fixed dose of Pembrolizumab in combination with two different regimens of hypofractionated radiation.
- Trial name
- NCT02880345
- Testing
- PEMBROLIZUMAB, hypofractionated radiation
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery…
- Conditions
- Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Serous Neoplasm
- Trial name
- NCT04575935
- Testing
- Chemotherapy, Laparotomy, Minimally Invasive Surgery
- Where
- 19 sites in United States, Canada and 3 more
- Volunteers
- 580 people
- Sponsor
- M.D. Anderson Cancer Center
Urothelial Carcinoma
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
This study plans to learn more about the combination of AMG 386 and docetaxel for the treatment of advanced urothelial cancer. Subjects are being asked to be in this research study because they have advanced urothelial cancer…
- Trial name
- NCT01907308
- Testing
- AMG 386, Docetaxel
- Sponsor
- University of Colorado, Denver
Advanced Urothelial Carcinoma, Metastatic Urothelial Cancer
Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma
This phase 1/2 study will evaluate the maximum tolerated dose, efficacy, and safety of clofarabine in patients with advanced or metastatic urothelial cancer.
- Trial name
- NCT07034053
- Testing
- Clofarabine
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Ekaterina Laukhtina
Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts.
- Trial name
- NCT06483334
- Testing
- Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab
- Where
- 25 sites in United States, Canada and 8 more
- Volunteers
- 38 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Urothelial Carcinoma, Bladder Cancer
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma
This is an open label, non-randomized phase 2 study of the combination of pembrolizumab and cabozantinib to assess overall response rate (ORR), progression free survival at 6 months (PFS6), and overall survival (OS) in patients…
- Trial name
- PemCab (NCT03534804)
- Testing
- Cabozantinib, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Utah
Recurrent Bladder Cancer, Stage I Bladder Cancer
Gene Therapy in Treating Patients With Advanced Bladder Cancer
Phase I trial to study the effectiveness of gene therapy in treating patients with advanced bladder cancer. Inserting the p53 gene into a person's bladder cancer cells may improve the body's ability to fight cancer
- Conditions
- Recurrent Bladder Cancer, Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer
- Trial name
- NCT00003167
- Testing
- Ad5CMV-p53 gene
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)